

Rena M Conti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4401912/publications.pdf>

Version: 2024-02-01

96
papers

3,992
citations

236612

25
h-index

123241

61
g-index

97
all docs

97
docs citations

97
times ranked

4966
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States. JAMA - Journal of the American Medical Association, 2008, 300, 2867.	3.8	809
2	Racial Disparities in Access to Renal Transplantation â€” Clinically Appropriate or Due to Underuse or Overuse?. New England Journal of Medicine, 2000, 343, 1537-1544.	13.9	531
3	Pricing in the Market for Anticancer Drugs. Journal of Economic Perspectives, 2015, 29, 139-162.	2.7	379
4	Impact of FDA Black Box Advisory on Antipsychotic Medication Use. Archives of Internal Medicine, 2010, 170, 96.	4.3	211
5	Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors. Medical Care, 2012, 50, 466-478.	1.1	185
6	Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. Journal of Clinical Oncology, 2013, 31, 1134-1139.	0.8	113
7	Overspending driven by oversized single dose vials of cancer drugs. BMJ, The, 2016, 352, i788.	3.0	109
8	Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities. Medical Decision Making, 2010, 30, 328-340.	1.2	99
9	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute, 2016, 108, djw003.	3.0	82
10	Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 2000â€”2010. Academic Pediatrics, 2012, 12, 110-116.	1.0	74
11	Mental Health Policy and Psychotropic Drugs. Milbank Quarterly, 2005, 83, 271-298.	2.1	65
12	Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults. JAMA Pediatrics, 2020, 174, 141.	3.3	60
13	Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiology and Drug Safety, 2010, 19, 834-842.	0.9	58
14	An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is â€”Worth Itâ€”™ In The Case Of Cancer. Health Affairs, 2012, 31, 667-675.	2.5	57
15	21st century pharmacovigilance: efforts, roles, and responsibilities. Lancet Oncology, The, 2016, 17, e486-e492.	5.1	55
16	Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. JAMA Internal Medicine, 2017, 177, 1185.	2.6	54
17	The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities. Health Affairs, 2014, 33, 1786-1792.	2.5	51
18	National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011. Health Affairs, 2014, 33, 1721-1727.	2.5	50

#	ARTICLE	IF	CITATIONS
19	Cost Consequences of the 340B Drug Discount Program. JAMA - Journal of the American Medical Association, 2013, 309, 1995.	3.8	48
20	Effect of FDA Investigation on Opioid Prescribing to Children After Tonsillectomy/Adenoidectomy. Pediatrics, 2017, 140, .	1.0	46
21	Use of Low-Value Pediatric Services Among the Commercially Insured. Pediatrics, 2016, 138, .	1.0	44
22	Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 1998â€“2009. Psychiatric Services, 2012, 63, 83-86.	1.1	42
23	Opioid Prescribing to US Children and Young Adults in 2019. Pediatrics, 2021, 148, .	1.0	40
24	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Annals of Hematology, 2015, 94, 249-257.	0.8	39
25	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2020, 77, 84-112.	0.5	29
26	Pharmaceutical Policy Reform â€” Balancing Affordability with Incentives for Innovation. New England Journal of Medicine, 2016, 374, 703-706.	13.9	28
27	Prescription Drug Dispensing to US Children During the COVID-19 Pandemic. Pediatrics, 2021, 148, .	1.0	28
28	The Economics of Comparative Effectiveness Studies. Pharmacoeconomics, 2010, 28, 843-853.	1.7	25
29	Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004â€“2008. Psychiatric Services, 2013, 64, 339-346.	1.1	25
30	Mitigating Financial Toxicity Among US Patients With Cancer. JAMA Oncology, 2017, 3, 765.	3.4	25
31	Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes. JAMA Internal Medicine, 2020, 180, 1012.	2.6	23
32	A pediatric-focused review of the performance incentive literature. Current Opinion in Pediatrics, 2007, 19, 719-725.	1.0	22
33	Payment for Oncolytics in the United States: A History of Buy and Bill and Proposals for Reform. Journal of Oncology Practice, 2014, 10, 357-362.	2.5	22
34	Antidepressant treatment and suicide attempts and selfâ€“inflicted injury in children and adolescents. Pharmacoepidemiology and Drug Safety, 2015, 24, 208-214.	0.9	21
35	Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020. JAMA Network Open, 2021, 4, e2129894.	2.8	21
36	Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children. Pediatrics, 2020, 145, .	1.0	20

#	ARTICLE	IF	CITATIONS
37	Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e75-e80.	1.8	19
38	Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005. Psychiatric Services, 2011, 62, 720-726.	1.1	18
39	Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. Annals of Emergency Medicine, 2022, 79, 225-236.	0.3	18
40	Appropriately Framing Child Health Care Spending. JAMA - Journal of the American Medical Association, 2018, 319, 1087.	3.8	17
41	Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016. JAMA Network Open, 2019, 2, e1914141.	2.8	17
42	US Insurer Spending on Ivermectin Prescriptions for COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 584.	3.8	17
43	A Pathway Through the Bundle Jungle. Journal of Oncology Practice, 2016, 12, 504-509.	2.5	16
44	National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. Journal of Urology, 2016, 195, 1383-1389.	0.2	16
45	Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases. Health Affairs, 2021, 40, 453-460.	2.5	16
46	Using Performance Data to Identify Preferred Hospitals. Health Services Research, 2007, 42, 2109-2119.	1.0	15
47	The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs. Medical Care, 2013, 51, 622-627.	1.1	11
48	Diversity of Participants in the 340B Drug Pricing Program for US Hospitals. JAMA Internal Medicine, 2018, 178, 1124.	2.6	11
49	Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions. Pediatric Cardiology, 2019, 40, 1599-1608.	0.6	11
50	Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids. JAMA Network Open, 2019, 2, e193673.	2.8	11
51	Four Facts Concerning Competition in US Generic Prescription Drug Markets. International Journal of the Economics of Business, 2020, 27, 27-48.	1.0	11
52	Pediatric Orphan Drug Indications: 2010-2018. Pediatrics, 2020, 145, .	1.0	11
53	Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?. Journal of Pharmaceutical Policy and Practice, 2018, 11, 29.	1.1	9
54	Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiology and Drug Safety, 2012, 21, 1251-1260.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017. <i>Value in Health</i> , 2019, 22, 1387-1395.	0.1	8
56	How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts. <i>Health Affairs</i> , 2020, 39, 445-452.	2.5	8
57	Projections of US Prescription Drug Spending and Key Policy Implications. <i>JAMA Health Forum</i> , 2021, 2, e201613.	1.0	8
58	Infused Chemotherapy Use in the Elderly After Patent Expiration. <i>Journal of Oncology Practice</i> , 2012, 8, e18s-e23s.	2.5	7
59	Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014. <i>JAMA Internal Medicine</i> , 2017, 177, 736.	2.6	7
60	The generic drug user fee amendments: an economic perspective. <i>Journal of Law and the Biosciences</i> , 2018, 5, 103-141.	0.8	7
61	Relationship between initiation of 340B participation and hospital safety-net engagement. <i>Health Services Research</i> , 2020, 55, 157-169.	1.0	7
62	Problems With Public Reporting of Cancer Quality Outcomes Data. <i>Journal of Oncology Practice</i> , 2014, 10, 215-218.	2.5	6
63	Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014. <i>Journal of General Internal Medicine</i> , 2019, 34, 338-340.	1.3	6
64	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	0.6	6
65	Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications. <i>JAMA Network Open</i> , 2021, 4, e2134142.	2.8	6
66	Nonprofit Biomedical Companies. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 194-197.	2.3	5
67	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. <i>Journal of Oncology Practice</i> , 2015, 11, 313-318.	2.5	5
68	Pharmacy Benefit Manager Reform. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 299.	3.8	5
69	The geography of prescription pharmaceuticals supplied to the USA: levels, trends, and implications. <i>Journal of Law and the Biosciences</i> , 2021, 8, Isaa085.	0.8	5
70	Infused chemotherapy use in the elderly after patent expiration. <i>American Journal of Managed Care</i> , 2012, 18, e173-8.	0.8	5
71	Pharmaceuticals and Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2083.	3.8	4
72	Biosimilars: Reimbursement Issues in Your Oncology Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 12s-14s.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013â€“18. Health Affairs, 2020, 39, 1806-1811.	2.5	4
74	Prevalence and Magnitude of Potential Surprise Bills for Childbirth. JAMA Health Forum, 2021, 2, e211460.	1.0	4
75	Public research funding and pharmaceutical prices: do Americans pay twice for drugs?. F1000Research, 2020, 9, 707.	0.8	4
76	Regulating Drug Prices while Increasing Innovation. New England Journal of Medicine, 2021, 385, 1921-1923.	13.9	4
77	Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change. Journal of Oncology Practice, 2015, 11, e95-e97.	2.5	3
78	60ÂYears after Kefauver: Household income required to buy prescription drugs in the United States and abroad. Research in Social and Administrative Pharmacy, 2020, 17, 1489-1495.	1.5	3
79	Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 90.	3.3	3
80	Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage. American Journal of Preventive Medicine, 2021, 60, 537-541.	1.6	3
81	Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. JAMA Internal Medicine, 2020, 180, 1273.	2.6	2
82	Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA. Journal of Health Politics, Policy and Law, 2017, 42, 377-385.	0.9	2
83	Trends in and Factors Associated With Out-of-Pocket Spending for COVID-19 Hospitalizations From March 2020 to March 2021. JAMA Network Open, 2022, 5, e2148237.	2.8	2
84	How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation?. JAMA Health Forum, 2021, 2, e214242.	1.0	2
85	THE ADVANTAGES OF AWARDED THE FEDERAL GOVERNMENT NEGOTIATING POWER OVER THE PRICES OF PRESCRIPTION DRUGS. Journal of Policy Analysis and Management, 2016, 35, 964-970.	1.1	1
86	The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1077-1085.	0.5	1
87	Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL). Blood, 2018, 132, 975-975.	0.6	1
88	The societal benefit of nonprofit biotechnology companies. Clinical Advances in Hematology and Oncology, 2008, 6, 366-7, 386.	0.3	1
89	Ensuring a high-quality and resilient supply chain of essential medications means paying more. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 573-576.	0.5	1
90	Drug Discount Programâ€”Reply. JAMA - Journal of the American Medical Association, 2013, 310, 1627.	3.8	0

#	ARTICLE	IF	CITATIONS
91	Improving Outpatient Oncology Practice: Several Steps Into a Long Journey. <i>Journal of Oncology Practice</i> , 2014, 10, 355-356.	2.5	0
92	Reply to M. Thompson et al. <i>Journal of Oncology Practice</i> , 2015, 11, 263-264.	2.5	0
93	RESPONSE TO JOYCE AND SOOD. <i>Journal of Policy Analysis and Management</i> , 2016, 35, 972-974.	1.1	0
94	Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU. <i>Hematologic Malignancies</i> , 2016, , 231-255.	0.2	0
95	Value of research analysis: an application to drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 298-300.	0.3	0
96	Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015â€“2019. <i>Journal of General Internal Medicine</i> , 0, , .	1.3	0